All In Biotech

Drug Trial Radar · NCT04433494

A Study of TY-302 in Patients With Advanced Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of TY-302 Capsules in Patients With Advanced Solid Tumors in China

Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 7, 2020

Primary completion

May 2023

Study completion Dec 2023

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: * TY-302 * Tamoxifen

Conditions

  • Breast Cancer
  • Solid Tumor

Interventions

  • TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mgDrug

    TY-302 is taken orally. Tamoxifen is taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302Time frame: 1 year
  2. Dose Limiting Toxicity (DLT) of TY-302Time frame: First 35 days of dosing
  3. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302 combine with TamoxifenTime frame: 1 year
  4. Dose Limiting Toxicity (DLT) of TY-302 combine with TamoxifenTime frame: First 28 days of dosing
  5. Overall Response Rate (ORR) of TY-302 combine with TamoxifenTime frame: 6 months
  6. Disease Control Rate(DCR) of TY-302 combine with TamoxifenTime frame: 9 months
  7. Duration of Response (DOR) of TY-302 combine with TamoxifenTime frame: 9 months
  8. Progression-free Survival (PFS) of TY-302 combine with TamoxifenTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences and Peking Union Medical Colledge

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.